Lantheus
Lantheus makes Pylarify, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026.
Pylarify/Pylarify TruVu, Neuraceq (amyloid), PNT2002 (177Lu-PSMA-I&T, SPLASH phase 3, missed OS), PNT2003 (177Lu-DOTATATE generic).
Piflufolastat F-18 (Pylarify) is the leading PSMA PET tracer for prostate cancer, with a new formulation approved in March 2026.
177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit.
Pages like this
not linked directly; found by shared links- TrialECLIPSE
Shares 177Lu-PSMA-I&T, Prostate cancer.
- TrialSPLASH
Shares 177Lu-PSMA-I&T, Prostate cancer.
- CompanyCurium
Shares 177Lu-PSMA-I&T, Radionuclide generators and cold kits, Prostate cancer.
- CompanyTelix Pharmaceuticals
Shares Radionuclide generators and cold kits, PET tracer manufacturing and distribution, Prostate cancer.
- PersonPeter Bartenstein
Shares 177Lu-PSMA-I&T, Prostate cancer.
- TechnologyMedical cyclotrons, hot cells, and synthesis modules
Shares Radionuclide generators and cold kits, PET tracer manufacturing and distribution.
- PairingPSMA PET → PSMA radioligand therapy
Shares Piflufolastat F-18 / Pylarify TruVu, Prostate cancer.
- TechnologyPSMA PET
Shares Piflufolastat F-18 / Pylarify TruVu, 177Lu-PSMA-I&T, Radionuclide generators and cold kits, PET tracer manufacturing and distribution.